- Home
- ETON vs VATE Comparison
ETON vs VATE Comparison
Compare ETON & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- VATE
- Stock Information
- Founded
- ETON 2017
- VATE 1994
- Country
- ETON United States
- VATE United States
- Employees
- ETON N/A
- VATE N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- VATE Metal Fabrications
- Sector
- ETON Health Care
- VATE Industrials
- Exchange
- ETON Nasdaq
- VATE Nasdaq
- Market Cap
- ETON 428.5M
- VATE 98.2M
- IPO Year
- ETON 2018
- VATE 1996
- Fundamental
- Price
- ETON $15.68
- VATE $5.50
- Analyst Decision
- ETON Strong Buy
- VATE
- Analyst Count
- ETON 3
- VATE 0
- Target Price
- ETON $29.67
- VATE N/A
- AVG Volume (30 Days)
- ETON 632.7K
- VATE 18.2K
- Earning Date
- ETON 08-07-2025
- VATE 08-06-2025
- Dividend Yield
- ETON N/A
- VATE N/A
- EPS Growth
- ETON N/A
- VATE N/A
- EPS
- ETON N/A
- VATE N/A
- Revenue
- ETON $48,327,000.00
- VATE $1,066,100,000.00
- Revenue This Year
- ETON $103.21
- VATE N/A
- Revenue Next Year
- ETON $51.34
- VATE N/A
- P/E Ratio
- ETON N/A
- VATE N/A
- Revenue Growth
- ETON 40.88
- VATE N/A
- 52 Week Low
- ETON $3.25
- VATE $3.25
- 52 Week High
- ETON $21.48
- VATE $13.79
- Technical
- Relative Strength Index (RSI)
- ETON 55.57
- VATE 49.15
- Support Level
- ETON $13.78
- VATE $5.20
- Resistance Level
- ETON $14.70
- VATE $5.62
- Average True Range (ATR)
- ETON 0.82
- VATE 0.25
- MACD
- ETON 0.30
- VATE 0.06
- Stochastic Oscillator
- ETON 89.31
- VATE 75.41
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.